Incyte Corporation (INCY) Earns Sector Perform Rating from Analysts at Royal Bank Of Canada

Royal Bank Of Canada started coverage on shares of Incyte Corporation (NASDAQ:INCY) in a report issued on Thursday, MarketBeat Ratings reports. The brokerage issued a sector perform rating and a $136.00 price objective on the biopharmaceutical company’s stock.

A number of other equities analysts also recently issued reports on the company. Argus reiterated a buy rating and issued a $150.00 price objective on shares of Incyte Corporation in a report on Wednesday. Oppenheimer Holdings, Inc. reiterated a hold rating and issued a $135.00 price objective on shares of Incyte Corporation in a report on Sunday, September 10th. BMO Capital Markets reiterated an outperform rating and issued a $163.00 price objective (down previously from $172.00) on shares of Incyte Corporation in a report on Monday, September 11th. Raymond James Financial, Inc. upgraded Incyte Corporation from a market perform rating to an outperform rating and set a $159.00 price objective for the company in a report on Monday, September 11th. Finally, J P Morgan Chase & Co reiterated a buy rating and issued a $149.00 price objective on shares of Incyte Corporation in a report on Thursday, August 31st. Eight research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. Incyte Corporation presently has a consensus rating of Buy and a consensus target price of $142.16.

Shares of Incyte Corporation (INCY) opened at 119.15 on Thursday. The firm’s market cap is $24.51 billion. Incyte Corporation has a 52-week low of $81.49 and a 52-week high of $153.15. The company has a 50-day moving average of $127.40 and a 200 day moving average of $130.21.

Incyte Corporation (NASDAQ:INCY) last posted its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). The firm had revenue of $326.40 million during the quarter, compared to the consensus estimate of $318.45 million. Incyte Corporation had a negative return on equity of 21.57% and a negative net margin of 11.77%. Incyte Corporation’s revenue for the quarter was up 32.5% compared to the same quarter last year. During the same quarter last year, the company posted $0.18 EPS. On average, equities analysts expect that Incyte Corporation will post ($0.84) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Incyte Corporation (INCY) Earns Sector Perform Rating from Analysts at Royal Bank Of Canada” was posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are viewing this report on another publication, it was stolen and republished in violation of United States & international copyright and trademark laws. The correct version of this report can be viewed at https://www.truebluetribune.com/2017/09/17/incyte-corporation-incy-earns-sector-perform-rating-from-analysts-at-royal-bank-of-canada.html.

In other news, Director Bros. Advisors Lp Baker bought 100,000 shares of the company’s stock in a transaction on Friday, September 8th. The shares were acquired at an average cost of $132.00 per share, with a total value of $13,200,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Steven H. Stein sold 9,883 shares of the firm’s stock in a transaction dated Tuesday, June 20th. The stock was sold at an average price of $125.00, for a total value of $1,235,375.00. Following the completion of the transaction, the executive vice president now directly owns 18,518 shares in the company, valued at $2,314,750. The disclosure for this sale can be found here. Insiders have sold 54,252 shares of company stock worth $7,206,984 over the last ninety days. 17.70% of the stock is currently owned by insiders.

Large investors have recently made changes to their positions in the business. D. Scott Neal Inc. purchased a new position in Incyte Corporation in the second quarter worth about $103,000. Tower Research Capital LLC TRC purchased a new position in Incyte Corporation in the first quarter worth about $105,000. Cornerstone Advisors Inc. boosted its position in Incyte Corporation by 19.6% in the second quarter. Cornerstone Advisors Inc. now owns 884 shares of the biopharmaceutical company’s stock worth $111,000 after purchasing an additional 145 shares during the last quarter. Exane Asset Management purchased a new position in Incyte Corporation in the second quarter worth about $126,000. Finally, Seven Eight Capital LP purchased a new position in Incyte Corporation in the second quarter worth about $129,000. 91.06% of the stock is currently owned by institutional investors and hedge funds.

About Incyte Corporation

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Analyst Recommendations for Incyte Corporation (NASDAQ:INCY)

Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply